

Iain B Mcinnes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5488448/iain-b-mcinnes-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118
papers

16,771
citations

43
h-index

129
g-index

141
ext. papers

21,185
ext. citations

10.1
avg, IF

6.81
L-index

#	Paper	IF	Citations
118	Long-term outcomes following severe COVID-19 infection: a propensity matched cohort study. <i>BMJ Open Respiratory Research</i> , 2021 , 8,	5.6	1
117	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	1
116	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	6
115	A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. <i>Rheumatology</i> , 2021 ,	3.9	4
114	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	5
113	Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	4
112	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2021 , 384, 1227-1239	59.2	41
111	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. <i>Rheumatology</i> , 2021 , 60, 5337-5350	3.9	4
110	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. <i>RMD Open</i> , 2021 , 7,	5.9	2
109	Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1494-1497	2.4	7
108	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. <i>Rheumatology</i> , 2021 , 60, 2109-2121	3.9	10
107	Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	10
106	Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naïve Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 604-616	9.5	16
105	Stromal Activation Markers do not confer pathogenic activity in tendinopathy. <i>Translational Sports Medicine</i> , 2021 , 4, 268-279	1.3	2
104	Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 185-193	2.4	26
103	IL-23 orchestrating immune cell activation in arthritis. <i>Rheumatology</i> , 2021 , 60, iv4-iv15	3.9	1
102	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	19

101	Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. <i>New England Journal of Medicine</i> , 2021 , 385, 628-639	59.2	26
100	Immune-mediated inflammatory disease therapeutics: past, present and future. <i>Nature Reviews Immunology</i> , 2021 , 21, 680-686	36.5	11
99	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. <i>Rheumatology and Therapy</i> , 2021 , 8, 1677-1691	4.4	
98	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. <i>British Journal of Dermatology</i> , 2020 , 182, 130-137	4	24
97	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020 , 395, 1496-1505	40	83
96	The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 349-356	5.3	7
95	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 700-712	2.4	238
94	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 760-770	2.4	112
93	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1126-1136	40	90
92	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020 , 395, 427-440	40	65
91	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. <i>Cardiovascular Research</i> , 2020 , 116, 1666-1687	9.9	714
90	In Human Autoimmunity, a Substantial Component of the B Cell Repertoire Consists of Polyclonal, Barely Mutated IgG B Cells. <i>Frontiers in Immunology</i> , 2020 , 11, 395	8.4	3
89	GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOLimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 490-498	2.4	18
88	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	2.4	851
87	Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 281-291	1.9	3
86	Attenuation of Dupuytren's fibrosis via targeting of the STAT1 modulated IL-13R α response. <i>Science Advances</i> , 2020 , 6, eaaz8272	14.3	7
85	Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2020 , 47, 539-547	4.1	12
84	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020 , 47, 854-864	4.1	7

83	Molecular imaging of inflammation - Current and emerging technologies for diagnosis and treatment. <i>Pharmacology & Therapeutics</i> , 2020 , 211, 107550	13.9	23
82	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019 , 49, 1457-1973	6.1	485
81	Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1660-1669	9.5	5
80	Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 497-510	2.1	11
79	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 1458-1467	4.1	10
78	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019 , 20, 429	2.8	39
77	Rheumatoid arthritis and depression: an inflammatory perspective. <i>Lancet Psychiatry</i> , 2019 , 6, 164-173	23.3	125
76	The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. <i>Rheumatology</i> , 2019 , 58, 197-205	3.9	40
75	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 988-995	2.4	31
74	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 18001	51.1	750
73	Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 579-588	2.4	16
72	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018 , 20, 47	5.7	69
71	P059 Ex vivo comparison of baricitinib, upadacitinib, filgotinib and tofacitinib for cytokine signalling in human leukocyte subpopulations 2018 ,		1
70	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320
69	Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 113	5.7	17
68	Model answers: Rational application of murine models in arthritis research. <i>European Journal of Immunology</i> , 2018 , 48, 32-38	6.1	15
67	multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy. <i>Theranostics</i> , 2018 , 8, 6195-6209	12.1	40
66	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 1107-1123	2.1	24

65	The extending scope of kinase inhibition in immune diseases. <i>Lancet, The</i> , 2018 , 392, 2328-2331	4.0	2
64	Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. <i>Scientific Reports</i> , 2017 , 7, 40473	4.9	24
63	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	7.4	1649
62	Elevated ACKR2 expression is a common feature of inflammatory arthropathies. <i>Rheumatology</i> , 2017 , 56, 1607-1617	3.9	7
61	Managing rheumatic and musculoskeletal diseases - past, present and future. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 443-448	8.1	74
60	Guidelines for the use of flow cytometry and cell sorting in immunological studies. <i>European Journal of Immunology</i> , 2017 , 47, 1584-1797	6.1	359
59	Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1949-1952	2.4	41
58	Targeting danger molecules in tendinopathy: the HMGB1/TLR4 axis. <i>RMD Open</i> , 2017 , 3, e000456	5.9	27
57	MicroRNA29a Treatment Improves Early Tendon Injury. <i>Molecular Therapy</i> , 2017 , 25, 2415-2426	11.7	34
56	Wounds that heal and wounds that don't - The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis. <i>Seminars in Cell and Developmental Biology</i> , 2017 , 61, 41-50	7.5	26
55	Spinal cord oligodendrocyte-derived alarmin IL-33 mediates neuropathic pain. <i>FASEB Journal</i> , 2016 , 30, 54-65	0.9	99
54	Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation. <i>Rheumatology</i> , 2016 , 55, 120-32	3.9	28
53	Assessment of murine collagen-induced arthritis by longitudinal non-invasive duplexed molecular optical imaging. <i>Rheumatology</i> , 2016 , 55, 564-72	3.9	16
52	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1984-1988	2.4	101
51	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. <i>Nature Communications</i> , 2016 , 7, 12970	17.4	72
50	MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in Rheumatoid Arthritis. <i>Rheumatology</i> , 2016 , 55, 2056-2065	3.9	63
49	A1.10 The GM-CSF/CCL17 axis in the rheumatoid synovial environment. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, A4.2-A5	2.4	
48	FRI0051 In Vivo Imaging To Characterise The Specificity, Function and Behavior of The CD4+ T Cells Initiating Articular Inflammation. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 444.2-444	2.4	

47	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 461	2.8	15
46	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. <i>Journal of Rheumatology</i> , 2016 , 43, 1713-7	4.1	62
45	Mast Cells Contribute to Porphyromonas gingivalis-induced Bone Loss. <i>Journal of Dental Research</i> , 2016 , 95, 704-10	8.1	22
44	A Cytomegalovirus Peptide-Specific Antibody Alters Natural Killer Cell Homeostasis and Is Shared in Several Autoimmune Diseases. <i>Cell Host and Microbe</i> , 2016 , 19, 400-8	23.4	17
43	Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. <i>Arthritis and Rheumatology</i> , 2016 , 68, 627-38	9.5	18
42	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1043-50	2.4	129
41	Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. <i>RMD Open</i> , 2016 , 2, e000287	5.9	30
40	OP0008 Synovial Fibroblast Proliferation Is Enhanced by MicroRNA-223 Delivery through Monocyte-Derived Microparticles. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 55.3-56	2.4	
39	A10.07 The kinetic cytokine/chemokine secretory profile in surgical models of osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, A75.2-A75	2.4	
38	Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. <i>Atherosclerosis</i> , 2016 , 254, 167-171	3.1	12
37	Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1812-1822	4.7	19
36	Psoriatic arthritis: embracing pathogenetic and clinical heterogeneity?. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 9-11	2.2	8
35	Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. <i>Pharmacological Reviews</i> , 2015 , 67, 280-309	22.5	224
34	Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin α Receptors. <i>Immunity</i> , 2015 , 42, 1100-15	32.3	134
33	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015 , 386, 1137-46	40	566
32	The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigens. <i>Immunology and Cell Biology</i> , 2015 , 93, 167-76	5	15
31	Cellular imaging in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 357-67	8.1	13
30	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015 , 373, 1329-39	59.2	508

29	Periodontitis in the absence of B cells and specific anti-bacterial antibody. <i>Molecular Oral Microbiology</i> , 2015 , 30, 160-9	4.6	34
28	The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4+ T cell-priming capacity of dendritic cells. <i>Rheumatology</i> , 2015 , 54, 169-77	3.9	12
27	Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency. <i>Journal of Clinical Lipidology</i> , 2015 , 9, 81-90	4.9	32
26	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 349-56	2.4	267
25	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1000-6	2.4	211
24	Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. <i>Arthritis Care and Research</i> , 2014 , 66, 19-26	4.7	43
23	Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014 , 28, 605-24	5.3	28
22	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 Trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 990-9	2.4	465
21	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <i>Lancet, The</i> , 2013 , 382, 780-9	4.0	557
20	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013 , 382, 1705-13	4.0	449
19	Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1445-52	2.4	125
18	Back to the future: oral targeted therapy for RA and other autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 173-82	8.1	81
17	Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 513-23	8.1	163
16	Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1448-56		98
15	OP0272 Abatacept is highly effective in inhibiting T cell priming but fails to induce T cell tolerance after primary antigen encounter. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 148.2-148	2.4	1
14	IL-33/ST2 signalling contributes to carrageenin-induced innate inflammation and inflammatory pain: role of cytokines, endothelin-1 and prostaglandin E2. <i>British Journal of Pharmacology</i> , 2013 , 169, 90-101	8.6	65
13	The pathogenesis of rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2011 , 365, 2205-19	59.2	3148
12	Arthritis in space and time--to boldly go!. <i>FEBS Letters</i> , 2011 , 585, 3640-8	3.8	2

11	Breach of self tolerance in rheumatoid arthritis: a role for Th17 effector T cells?. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, A50-A50	2.4	
10	Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1281-5	2.4	42
9	Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009 , 60, 976-86		467
8	Does practice mirror the evidence base in the treatment of rheumatoid arthritis?. <i>Clinical Rheumatology</i> , 2009 , 28, 961-70	3.9	1
7	Interleukin-18: a therapeutic target in rheumatoid arthritis?. <i>Arthritis Research</i> , 2005 , 7, 38-41		40
6	Inducing experimental arthritis and breaking self-tolerance to joint-specific antigens with trackable, ovalbumin-specific T cells. <i>Journal of Immunology</i> , 2004 , 173, 151-6	5.3	43
5	A novel therapeutic approach targeting articular inflammation using the filarial nematode-derived phosphorylcholine-containing glycoprotein ES-62. <i>Journal of Immunology</i> , 2003 , 171, 2127-33	5.3	173
4	Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. <i>Journal of Experimental Medicine</i> , 1998 , 188, 1485-92	16.6	307
3	Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. <i>Nature Medicine</i> , 1997 , 3, 189-95	50.5	626
2	The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. <i>Nature Medicine</i> , 1996 , 2, 175-82	50.5	418
1	Evidence of a common causal relationship between body mass index and inflammatory skin disease: a Mendelian Randomization study		2